Truth or Perception: Demystifying Emergent Data in the Competitive Endometrial Cancer Landscape
Industry Supported Symposium

This educational program is aimed at providing clarity in the treatment landscape of endometrial cancers. With a focus on synthesizing emerging data and debunking misconceptions, this course aims to unravel the complexities surrounding the design of clinical trials and the significance of emerging biomarkers in the field.   Throughout the session, participants will delve into key studies such as RUBY Parts I & II, GY018, ATTEND, DUO-E, B21 and other relevant endometrial trial data, exploring intriguing hypothesis-generating subgroup analyses, secondary endpoints, and trial eligibility nuances. Biomarkers, both prognostic and predictive, will be a pivotal topic of discussion, particularly exploring when and how clinicians obtain this information, how it is used to inform clinical trial results, and how it impacts clinical treatment decision-making.  To foster interactive engagement, attendees will have the opportunity to ask questions about the studies to promote a dynamic and participatory learning experience. Through shorter talks and ample discussion time, participants will gain valuable insights and clarity on the ever-evolving landscape of endometrial cancer treatment.

The GOG Foundation, Inc. is grateful for our commercial supporter for this symposium: GSK

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate increased knowledge regarding:

• Analyze and interpret emerging data from key endometrial cancer studies, including RUBY Parts I&II, GY018, ATTEND, DUO-E, B21 and other relevant trials, to gain a comprehensive understanding of treatment outcomes and therapeutic trends in the field.
• Evaluate the design complexities of clinical trials in endometrial cancer research, critically assessing study methodologies and identifying potential sources of confusion or bias that may impact data interpretation and clinical decision-making.
• Examine the significance of emerging biomarkers in endometrial cancer management, including their role in patient selection (e.g. immune checkpoint inhibitors (ICI), PARP inhibitor (PARPi) therapy) and their potential impact on treatment efficacy, sequencing and patient outcomes.
• Engage in interactive discussions and question-and-answer sessions to clarify misconceptions and deepen understanding of key concepts, fostering a collaborative learning environment that encourages active participation and knowledge exchange among participants.

Moderators

Dr. Matthew Powell

Dr. Thomas Herzog

Faculty

Dr. Robert Coleman

Dr. Mansor Mirza

Dr. Isabelle Ray-Coquard

Agenda

Truth or perception: Demystifying Emergent Data in the Competitive Endometrial Cancer Landscape,
an Industry Supported Symposium at the IGCS 2024 Annual Global Meeting

This session is not included in the main event CME/CPD credit.

View Recording